ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
April 01 2014 - 9:00AM
Business Wire
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 13th Annual Needham
Healthcare Conference on Tuesday, April 8, 2014, at 8:40 a.m.
Eastern Time in New York City.
A live webcast of ACADIA’s presentation will be accessible on
the company’s website, www.acadia-pharm.com, under the investors
section and an archived recording will be available on the website
through April 22, 2014.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines that address unmet
medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by
pimavanserin, which is in Phase III development as a potential
first-in-class treatment for Parkinson’s disease psychosis.
Pimavanserin is also in Phase II development for Alzheimer’s
disease psychosis and has successfully completed a Phase II trial
as a co-therapy for schizophrenia. ACADIA also has clinical-stage
programs for chronic pain and glaucoma in collaboration with
Allergan, Inc. and two advanced preclinical programs directed at
Parkinson’s disease and other neurological disorders. All product
candidates are small molecules that emanate from internal
discoveries. ACADIA maintains a website at www.acadia-pharm.com to
which ACADIA regularly posts copies of its press releases as well
as additional information and through which interested parties can
subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
progress and timing of ACADIA’s drug discovery and development
programs, either alone or with a partner, including clinical
trials, and the benefits to be derived from ACADIA’s product
candidates, in each case including pimavanserin. These statements
are only predictions based on current information and expectations
and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development and
commercialization, and collaborations with others, and the fact
that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year
ended December 31, 2013 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
ACADIA Pharmaceuticals Inc.Thomas H. Aasen, Executive Vice
President,Chief Financial Officer and Chief Business OfficerLisa
Barthelemy, Director of Investor Relations(858) 558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024